Shandong Sinobioway Biomedicine (002581.SZ) announced that the company's Board of Directors has reviewed and approved the "Agreement on Signing the Technical..."
According to the announcement from Zhito Finance APP, Shandong Sinobioway Biomedicine (002581.SZ) stated that the Board of Directors has reviewed and approved the proposal to sign the "Drug Clinical Trial Technical Service Agreement". The company agrees that its wholly-owned subsidiary, ShanDong Yandu Biotechnology Co., Ltd. (referred to as "ShanDong Yandu"), will sign the "Drug Clinical Trial Technical Service Agreement" with Tianjin Happy Life Technology Co., Ltd. (referred to as "Happy Life") for the planned Phase III clinical trial study of recombinant human nerve growth factor eye drops, hiring Happy Life to provide clinical trial technical services. The total cost for this clinical trial service amounts to 55.8176 million yuan.